EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An untargeted metabolomic analysis of acute AFB1 treatment in liver, breast, and lung cells

Heidi H Cao, Sabrina Molina, Susan Sumner, Blake R Rushing iD

PLOS ONE · 30.01.2025 · 20 (1) · e0313159

DOI: 10.1371/journal.pone.0313159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 30.01.2025. Verfasst von Heidi H Cao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America. Hauptthemen laut MEDLINE: Aflatoxin B1, Metabolomics, Metabolome, Liver. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIEHS NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aflatoxin B1 (AFB1) is a class 1 carcinogen and mycotoxin known to contribute to the development of hepatocellular carcinoma (HCC), growth impairment, altered immune system modulation, and malnutrition. AFB1 is synthesized by Aspergillus flavus and is known to widely contaminate foodstuffs, particularly maize, wheat, and groundnuts. The mechanism in which AFB1 causes genetic mutations has been well studied, however its metabolomic effects remained largely unknown. A better understanding of how AFB1 disrupts metabolism would provide insight into how this mycotoxin leads to carcinogenesis, growth impairment, and/or immunomodulation, and may reveal potential targets for pharmacological or nutritional interventions to protect against these effects. The current study evaluated the metabolomic effects of various doses (2.5 μM, 5 μM, 10uM) of AFB1 treatment to HepG2 (liver), MDA-MB-231 (breast), and A549 (lung) cells. Treated and control cells’ metabolomic profiles were evaluated via ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS). Univariate and multivariate analyses revealed significant alterations in metabolite concentrations from each dose of AFB1 treatment in each cell type. Pathway analysis was then used to understand broader biochemical functions affected by AFB1 treatment in each cell type. HepG2 cell pathway analyses revealed significant pathway perturbations in lipid metabolism, carnitine synthesis, catecholamine biosynthesis, purine metabolism, and spermidine and spermine biosynthesis. Analysis of A549 cells found a greater emphasis of perturbations on various amino acids along with lipid synthesis-related pathways, and catecholamine biosynthesis. Finally, analysis of treated MDA-MB-231 cells found spermidine and spermine biosynthesis, carnitine synthesis, plasma membrane-related pathways (phosphatidylcholine synthesis and alpha linolenic acid and linoleic acid metabolism), and various amino acid metabolism pathways to be most affected. These highlighted pathways should be targeted in future investigations to evaluate their potential in mitigating or preventing the development of negative health effects associated with AFB1 exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aflatoxin B1MetabolomicsMetabolomeLiverLungBreastHumansFemaleHep G2 CellsCell Line, TumorA549 Cells

Substanzen

Aflatoxin B1

Autor:innen und Institutionen

  • Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
  • Nutrition Research Institute, University of North Carolina Chapel Hill, Kannapolis, NC, United States of America.

ORCID-Profile: Blake R Rushing

Förderung

  • NIDDK NIH HHS
  • NIEHS NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Cao, H. H., Molina, S., Sumner, S., & Rushing, B. R. (2025). An untargeted metabolomic analysis of acute AFB1 treatment in liver, breast, and lung cells. PLOS ONE, 20(1), e0313159. https://doi.org/10.1371/journal.pone.0313159

Vancouver

Cao HH, Molina S, Sumner S, Rushing BR. An untargeted metabolomic analysis of acute AFB1 treatment in liver, breast, and lung cells. PLOS ONE. 2025;20(1):e0313159. doi:10.1371/journal.pone.0313159

BibTeX
@article{Cao2025,
  author = {Cao, Heidi H and Molina, Sabrina and Sumner, Susan and Rushing, Blake R},
  title = {An untargeted metabolomic analysis of acute AFB1 treatment in liver, breast, and lung cells},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {1},
  pages = {e0313159},
  doi = {10.1371/journal.pone.0313159}
}
Kostenlos starten →